Trial · NCT03487913
Results by group521
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 521
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Lixivaptan in ADPKD Patients | High Dose Lixivaptan / CKD1 or CKD2 | Day 1 (am) | 656.8 | Geometric Coefficient of Variation 28.1 | ng/mL |
| Maximum Observed Plasma Concentration (Cmax) of Lixivaptan in ADPKD Patients | Low Dose Lixivaptan / CKD1 or CKD2 | Day 1 (am) | 190.9 | Geometric Coefficient of Variation 52.0 | ng/mL |
| Maximum Observed Plasma Concentration (Cmax) of Lixivaptan in ADPKD Patients | High Dose Lixivaptan / CKD3 | Day 1 (am) | 681.3 | Geometric Coefficient of Variation 45.9 | ng/mL |
| Maximum Observed Plasma Concentration (Cmax) of Lixivaptan in ADPKD Patients | Low Dose Lixivaptan / CKD3 | Day 1 (am) | 156.9 | Geometric Coefficient of Variation 66.9 | ng/mL |
| Maximum Observed Plasma Concentration (Cmax) of Lixivaptan in ADPKD Patients | High Dose Lixivaptan / CKD1 or CKD2 | Day 1 (pm) | 1007 | Geometric Coefficient of Variation 36.6 | ng/mL |
| Maximum Observed Plasma Concentration (Cmax) of Lixivaptan in ADPKD Patients | Low Dose Lixivaptan / CKD1 or CKD2 | Day 1 (pm) | 211.5 | Geometric Coefficient of Variation 33.5 | ng/mL |
| Maximum Observed Plasma Concentration (Cmax) of Lixivaptan in ADPKD Patients | High Dose Lixivaptan / CKD3 | Day 1 (pm) | 930.2 | Geometric Coefficient of Variation 44.5 | ng/mL |
| Maximum Observed Plasma Concentration (Cmax) of Lixivaptan in ADPKD Patients | Low Dose Lixivaptan / CKD3 | Day 1 (pm) | 159.5 | Geometric Coefficient of Variation 51.9 | ng/mL |
| Maximum Observed Plasma Concentration (Cmax) of Lixivaptan in ADPKD Patients | High Dose Lixivaptan / CKD1 or CKD2 | Day 7 (am) | 1442 | Geometric Coefficient of Variation 34.3 | ng/mL |
| Maximum Observed Plasma Concentration (Cmax) of Lixivaptan in ADPKD Patients | Low Dose Lixivaptan / CKD1 or CKD2 | Day 7 (am) | 339.5 | Geometric Coefficient of Variation 19.5 | ng/mL |
| Maximum Observed Plasma Concentration (Cmax) of Lixivaptan in ADPKD Patients | High Dose Lixivaptan / CKD3 | Day 7 (am) | 1422 | Geometric Coefficient of Variation 48.3 | ng/mL |
| Maximum Observed Plasma Concentration (Cmax) of Lixivaptan in ADPKD Patients | Low Dose Lixivaptan / CKD3 | Day 7 (am) | 276.9 | Geometric Coefficient of Variation 33.7 | ng/mL |
| Maximum Observed Plasma Concentration (Cmax) of Lixivaptan in ADPKD Patients | High Dose Lixivaptan / CKD1 or CKD2 | Day 7 (pm) | 1582 | Geometric Coefficient of Variation 45.8 | ng/mL |
| Maximum Observed Plasma Concentration (Cmax) of Lixivaptan in ADPKD Patients | Low Dose Lixivaptan / CKD1 or CKD2 | Day 7 (pm) | 301.0 | Geometric Coefficient of Variation 13.7 | ng/mL |
| Maximum Observed Plasma Concentration (Cmax) of Lixivaptan in ADPKD Patients | High Dose Lixivaptan / CKD3 | Day 7 (pm) | 1211 | Geometric Coefficient of Variation 90.5 | ng/mL |
| Maximum Observed Plasma Concentration (Cmax) of Lixivaptan in ADPKD Patients | Low Dose Lixivaptan / CKD3 | Day 7 (pm) | 258.8 | Geometric Coefficient of Variation 38.4 | ng/mL |
| Maximum Observed Plasma Concentration (Cmax) of WAY-141624 in ADPKD Patients | High Dose Lixivaptan / CKD1 or CKD2 | Day 1 (am) | 455.3 | Geometric Coefficient of Variation 33.3 | ng/mL |
| Maximum Observed Plasma Concentration (Cmax) of WAY-141624 in ADPKD Patients | Low Dose Lixivaptan / CKD1 or CKD2 | Day 1 (am) | 123.7 | Geometric Coefficient of Variation 69.7 | ng/mL |
| Maximum Observed Plasma Concentration (Cmax) of WAY-141624 in ADPKD Patients | High Dose Lixivaptan / CKD3 | Day 1 (am) | 381.7 | Geometric Coefficient of Variation 46.6 | ng/mL |
| Maximum Observed Plasma Concentration (Cmax) of WAY-141624 in ADPKD Patients | Low Dose Lixivaptan / CKD3 | Day 1 (am) | 135.3 | Geometric Coefficient of Variation 55.5 | ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03487913/results